Clinical trials
Thrombocytopenia clinical trials
Below are recruiting thrombocytopenia clinical trials, each written for real people, not researchers. We’re tracking 147 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07095127RecruitingPhase 2
Testing NVG-2089 for immune thrombocytopenia
This trial tests an investigational drug called NVG-2089 for adults with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. The goal is to see if it safely raises platelet counts and improves bleeding symptoms.
Greenville, North CarolinaAges 18–80 - NCT07110090RecruitingPhase 1
Umbilical cord blood shot for low platelets after cancer treatment
This trial tests an injection made from umbilical cord blood to raise low platelet counts caused by cancer therapies like chemo, immunotherapy, or radiation. It may help people with mild to moderate low platelets who haven't had recent platelet transfusions or other platelet-raising drugs.
Beijing, Beijing MunicipalityAges 18–75 - NCT07206758RecruitingPhase 1
Study of SHR-2173 for immune thrombocytopenia (ITP)
This study tests a new medication called SHR-2173 for people with immune thrombocytopenia (ITP) whose platelet count is low and who have already tried steroids without success. The goal is to see if this drug can help raise platelet counts and reduce bleeding risk.
Wuhan, HubeiAges 18 years+ - NCT07233213RecruitingPhase 3
IVIG for chronic low platelet condition
This trial tests an intravenous immunoglobulin (IVIG) treatment for chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, causing low counts and bleeding risk. It aims to safely raise platelet levels using donated antibodies.
Ankara, AltındağAges 18–65 - NCT07234019RecruitingPhase 2
Rituximab plus anti-CD38 antibody for ITP
This trial tests whether adding an anti-CD38 antibody to the standard drug rituximab works better than rituximab alone for adults with long-term immune thrombocytopenia (ITP) who have already tried steroids without lasting success.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07294365RecruitingPhase 2
Study of DZD8586 for adults with chronic ITP
This study tests an investigational drug called DZD8586 for people with long-term ITP (low platelets) that hasn't improved with standard treatments. The goal is to see if it can safely raise platelet counts and reduce bleeding risk.
Jinan, ShandongAges 18 years+ - NCT07297563RecruitingPhase 2
Anti-CD38 antibody vs rituximab for hard-to-treat ITP
This trial tests a new antibody drug (anti-CD38) compared to a standard drug (rituximab) for adults with ITP that hasn't responded well to steroids. The goal is to see if the new drug works better at raising platelet counts and reducing bleeding risk.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07362199RecruitingPhase 2
New combo treatment for chronic ITP
This trial tests combining two antibodies (anti-CD38 and rituximab) for adults with chronic ITP who haven't been helped by steroids or other standard treatments. The goal is to see if this drug pair can raise platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07362238RecruitingPhase 2
Daratumumab vs Rituximab for pediatric ITP
This study compares daratumumab to rituximab for children with primary immune thrombocytopenia (ITP) that hasn't improved with steroids. The goal is to find a better treatment to raise platelet counts and reduce bleeding risk.
TianjinAges 6–18 - NCT02877706Recruiting
Registry study for newly diagnosed ITP or AIHA
This study is a registry that collects medical information from adults who are newly diagnosed with immune thrombocytopenia (ITP) or autoimmune hemolytic anemia (AIHA), or who are starting a treatment called fosfamatinib. It can help doctors understand these conditions better and improve future care.
ToulouseAges 18 years+ - NCT07446491RecruitingPhase 1/Phase 2
PN20 for low platelets in liver disease patients needing a procedure
This study tests a new medicine called PN20 to safely raise platelet counts in people with chronic liver disease who need a minor procedure (like a biopsy). It's for patients whose platelet count is below 50 and whose liver disease is not too severe.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07559331RecruitingPhase 3
Dexamethasone plus Orelabrutinib for newly diagnosed immune thrombocytopenia
This trial tests whether adding a drug called orelabrutinib to high-dose dexamethasone (a steroid) works better than dexamethasone alone for treating newly diagnosed immune thrombocytopenia (ITP)—a condition where your body destroys its own platelets, causing very low blood counts. The goal is to see if the combination helps raise your platelet count and prevents bleeding.
Jinan, ShandongAges 18–80 - NCT07605845RecruitingPhase 1
Testing GL-2045 Safety in Immune Thrombocytopenia Patients
This trial tests a new drug called GL-2045 for immune thrombocytopenia (ITP)—a condition where your body destroys its own platelets, causing low platelet counts and bleeding risks. The study checks if GL-2045 is safe and effective for people whose platelet counts haven't been controlled well enough with other treatments.
LeedsAges 18–80 - NCT07657793RecruitingPhase 2/Phase 3
Sirolimus for Lupus-Related Low Platelets
This trial tests sirolimus, an immune-system-calming medicine, for people with lupus who also have very low platelet counts (ITP). It may help reduce bleeding risk and improve platelet numbers.
Beijing, Beijing MunicipalityAges 18–65 - NCT07757789Recruiting
Platelet changes in antiphospholipid syndrome
This study looks at how platelet counts change over time in people with antiphospholipid syndrome (APS), a condition that can cause blood clots and pregnancy problems. It may help doctors better understand and manage low platelets in APS patients.
Al Khārjah, Kharga OasisAges 18 years+ - NCT06948318RecruitingPhase 3
Follow-up study of mezagitamab for chronic ITP
This study follows up with adults who completed a previous mezagitamab trial for chronic immune thrombocytopenia (ITP). It monitors long-term safety and effectiveness of the treatment.
Hot Springs, ArkansasAges 18 years+ - NCT06722235RecruitingPhase 3
Mezagitamab for chronic ITP that hasn't responded to standard treatments
This study tests a new medicine called mezagitamab for adults with chronic ITP (low platelets for at least a year) who have not responded well to standard treatments. It aims to see if mezagitamab can safely raise platelet counts.
Hot Springs, ArkansasAges 18 years+ - NCT07068126Recruiting
New treatment for kids with lasting ITP
This trial tests a new approach for children ages 1 to 10 who have had ITP for 3–12 months. It aims to find a better way to manage the condition and improve platelet counts.
AsyutAges 1–10 - NCT05520892RecruitingPhase 4
IVIG dose options for newly diagnosed childhood ITP
This study compares two intravenous (IV) IgG treatment regimens for children newly diagnosed with immune thrombocytopenia (ITP). It aims to find a regimen that works well and is safe for raising low platelet counts.
Fuzhou, FujianAges 4 weeks–14 years - NCT04890041Recruiting
Testing TPO medicines for immune low platelets in teens
This trial studies whether “TPO” medicines (like eltrombopag or similar drugs) help people age 14 and older with primary immune thrombocytopenia (ITP) who did not respond well to first treatments. It may help raise platelet counts and reduce bleeding, especially when prior therapy hasn’t worked.
Tianjin, Tianjin MunicipalityAges 14 years+ - NCT06769685Enrolling by invitation
Platelet-boosting drug for solid tumor patients with low platelets
This trial tests if combining two platelet-raising drugs (TPO and a TPO receptor agent) can help patients with solid tumors who have very low platelets after cancer treatment. It aims to prevent or treat severe platelet drops.
Jinhua, ZhejiangAges 18 years+ - NCT06759636RecruitingPhase 3
Comparing two drugs for low platelets from cancer treatment
This trial tests if a new drug called Romiplostim N01 works better than the standard drug Interleukin-11 for raising low platelet counts caused by cancer treatments like chemotherapy or radiation. If you have low platelets from your cancer therapy, you may be able to join.
Nanjing, JiangsuAges 18–75 - NCT06479304Recruiting
Hydroxychloroquine plus prednisone for ANA-positive ITP
This study tests whether a combination of hydroxychloroquine (HCQ) and prednisone (a steroid) is safe and effective for treating immune thrombocytopenia (ITP) in people who have a positive ANA blood test. It may be an option for those with low platelets and bleeding risk.
Shanghai, Shanghai MunicipalityAges 15–99 - NCT06479317Recruiting
Combining hydroxychloroquine and dexamethasone for ITP with positive ANA
This trial tests if adding hydroxychloroquine (HCQ) to the steroid dexamethasone (DEX) works better than dexamethasone alone for adults with immune thrombocytopenia (ITP) who have a positive antinuclear antibody (ANA) blood test. The goal is to see if this combination can safely raise platelet counts and reduce bleeding risk.
Shanghai, Shanghai MunicipalityAges 15–75
Hear when a new Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for thrombocytopenia?
- Yes. Clin2 currently lists 147 recruiting thrombocytopenia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a thrombocytopenia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a thrombocytopenia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.